全文获取类型
收费全文 | 1010篇 |
免费 | 89篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 6篇 |
妇产科学 | 22篇 |
基础医学 | 169篇 |
口腔科学 | 4篇 |
临床医学 | 53篇 |
内科学 | 90篇 |
皮肤病学 | 7篇 |
神经病学 | 26篇 |
特种医学 | 12篇 |
外科学 | 64篇 |
综合类 | 156篇 |
预防医学 | 15篇 |
眼科学 | 4篇 |
药学 | 137篇 |
中国医学 | 10篇 |
肿瘤学 | 375篇 |
出版年
2024年 | 1篇 |
2023年 | 6篇 |
2022年 | 7篇 |
2021年 | 14篇 |
2020年 | 5篇 |
2019年 | 12篇 |
2018年 | 16篇 |
2017年 | 15篇 |
2016年 | 24篇 |
2015年 | 34篇 |
2014年 | 57篇 |
2013年 | 85篇 |
2012年 | 61篇 |
2011年 | 103篇 |
2010年 | 95篇 |
2009年 | 93篇 |
2008年 | 96篇 |
2007年 | 84篇 |
2006年 | 94篇 |
2005年 | 84篇 |
2004年 | 46篇 |
2003年 | 63篇 |
2002年 | 25篇 |
2001年 | 17篇 |
2000年 | 9篇 |
1999年 | 2篇 |
1998年 | 4篇 |
1997年 | 1篇 |
1996年 | 1篇 |
排序方式: 共有1154条查询结果,搜索用时 15 毫秒
991.
Vanesa Martín Guillermo García-Santos Jezabel Rodriguez-Blanco Sara Casado-Zapico Ana Sanchez-Sanchez Isaac Antolín Maria Medina Carmen Rodriguez 《Cancer letters》2010
Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels. 相似文献
992.
《Drug delivery》2013,20(2):78-85
AbstractWe have developed and characterized micellar formulations of analogs to the recently developed inhibitor of the phosphatidylinositol-3-kinase (PI3K) pathway (N-[(2-hydroxy-5-nitrophenyl)amino]carbonothioyl-3,5-dimethylbenzamide (DM-PIT-1)) for their physicochemical, loading and cytotoxic properties. The first generation inhibitor DM-PIT-1 is a non-lipid, small molecule inhibitor of phosphatidylinositol-3,4,5-triphosphate/Pleckstrin homology (PIP3/PH) binding capable of inhibiting the growth of tumor cells both in vitro and in vivo. A second generation of improved and druggable analogs has been developed. All compounds were successfully loaded (>70%) in PEG2000-PE micelles of 16–20?nm in size with several analogs demonstrating favorable cytotoxic activity against A2780 ovarian carcinoma. These compounds were also successfully incorporated into polyethylene glycol-phosphatidylethanolamine (PEG-PE) micelles combined with surface-bound tumor necrosis factor related apoptosis inducing ligand (TRAIL). The resulting multifunctional combination micelles were able to significantly enhance cytotoxic activity in the TRAIL-resistant A2780 cell line. Additionally, analogs NCL-176 and NCL-240 were effective in inhibiting tumor growth in an in vivo subcutaneous tumor model of A2780. These results indicate the utility of delivering TRAIL and PI3K pathway inhibitors in a combined micellar preparation. 相似文献
993.
Mise en abyme meaning “placed into abyss or infinite recurrence” is an apt paradigm for the relentless growth of sarcoma cells. Its alternative meaning, “self-reflexive embedding” fits the central role attributed to cancer stem cells (CSCs). Diversely sourced and defined, mesenchymal stem cells (MSCs) may be the cells of sarcoma origin, evolve a CSC phenotype and/or contribute to tumor growth through inherent qualities for homing, neovascularization, paracrine cross-feeding, microvesicle secretion, cell fusion, entosis and immune modulation. Exploiting these qualities, MSC expressing modified forms of the TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) are being developed to complement more conventional radiation and chemotherapy. 相似文献
994.
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a TNF superfamily member that is being considered as a new strategy in anticancer therapy because of its ability to induce apoptosis, alone or in combination with other stimuli, in many cancer cells. AMP-activated protein kinase (AMPK) is an evolutionarily conserved key regulator of cellular energy homeostasis that protects the cell from energy depletion and stress by activating several biochemical pathways that lead to the conservation, as well as generation, of ATP. Here we report that a number of AMPK activators, including the small molecule activator A-769662, markedly sensitize TRAIL-resistant breast cancer cells to TRAIL-induced apoptosis. However, silencing AMPKα1 expression with siRNA or over-expression of DN-AMPKα1 does not inhibit AICAR, glucose deprivation, phenformin or A-769662-induced sensitization to TRAIL. Furthermore, the expression of constitutively active AMPK subunits does not sensitize resistant breast cancer cells to TRAIL-induced apoptosis. The cellular FLICE-inhibitory proteins (cFLIPL and cFLIPS) were significantly down-regulated following exposure to AMPK activators through an AMPK-independent mechanism. Furthermore, in cells over-expressing cFLIPL, sensitization to TRAIL by AMPK activators was markedly reduced. In summary, our results indicate that AMPK activators facilitate the activation by TRAIL of an apoptotic cell death program through a mechanism independent of AMPK and dependent on the down-regulation of cFLIP levels. 相似文献
995.
Zev A. Wainberg Wells A. Messersmith Parvin F. Peddi Amy V. Kapp Avi Ashkenazi Stephanie Royer-Joo Chia C. Portera Mark F. Kozloff 《Clinical colorectal cancer》2013,12(4):248-254
ObjectivesThe study objectives were to evaluate the safety, tolerability, and preliminary efficacy of multiple doses of dulanermin in combination with modified FOLFOX6 and bevacizumab in previously untreated patients with locally advanced, recurrent, or metastatic colorectal cancer.Patients and MethodsA total of 23 patients received dulanermin at dosages of 4.5 or 9 mg/kg/d given on days 1 to 3 of each 14-day cycle along with standard dosing of modified FOLFOX6 plus bevacizumab. Dose-limiting toxicities, adverse events (AEs), maximum tolerated dose, and response according to Response Evaluation Criteria in Solid Tumors were assessed.ResultsIn the first cohort (3 patients given dulanermin at 4.5 mg/kg/d) and second cohort (6 patients given dulanermin at 9 mg/kg/day), no dose-limiting toxicities were observed. The subsequent 14 patients were treated with a dulanermin dosage of 9 mg/kg/d. Patients (N = 23) received 2 to 42 cycles of dulanermin (median 15). The most common grade 3 or 4 AEs were neutropenia (39%), hypertension (17%), peripheral neuropathy (17%), hand-foot syndrome (13%), and pulmonary embolism (13%). Three patients (13%) discontinued the study because of serious AEs. Overall, a best response of partial response was observed in 13 patients (57%) (9 confirmed, 4 unconfirmed), stable disease was observed in 7 patients (30%), and disease progression was observed in 3 patients (13%). The median progression-free survival was 9.9 months (95% confidence interval, 7.0-12.7).ConclusionsOverall, the addition of dulanermin to first-line FOLFOX plus bevacizumab was well tolerated in patients with advanced colorectal cancer, with similar AEs that would be expected from FOLFOX plus bevacizumab. A randomized study is required to assess the clinical efficacy of dulanermin in this patient population. 相似文献
996.
目的研究TRAIL联合顺铂诱导HOS-8603细胞的凋亡及其机制。方法 MTT法分别测定TRAIL,顺铂,和TRAIL+顺铂对HOS-8603细胞的抑制率,流式细胞法测定亚G1期细胞百分率及PI和Rh123双染色后细胞的ΔΨm。结果三组分别由TRAIL、顺铂、TRAIL+顺铂处理过的HOS-8603细胞用MTT法测抑制率分别为29%、33.6%、58.5%。随着药物作用时间增加,HOS-8603细胞凋亡数增加和ΔΨm降低(P<0.01),两者呈直线相关。结论 TRAIL和顺铂能协同诱导HOS-8603细胞凋亡,其机制可能是通过使线粒体膜通透性转运孔开放,ΔΨm降低来实现的。 相似文献
997.
Wei Zhu Hongwei Zhang Yi Shi Mangen Song Bijun Zhu Lai Wei 《Cancer biology & therapy》2013,14(11):1016-1023
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising cancer therapeutic target due to its selective apoptosis-inducing effect in cancer cells. To efficiently deliver TRAIL to the tumor cells, an oncolytic adenovirus (p55-hTERT-HRE-TRAIL) carrying the TRAIL coding sequence was constructed. In the present study, we aimed to investigate the effect of p55-hTERT-HRE-TRAIL on the growth and metastasis of triple-negative breast cancer (TNBC). We observed that infection of the recombinant adenovirus resulted in expression of TRAIL and massive cell death in a TNBC cell line MDA-MB-231. This effect is much weaker in MCF-10A, which is a normal breast cell line. Administration of P55-HTERT-HRE-TRAIL significantly reduced orthotopic breast tumor growth and extended survival in a metastatic model. Our results suggest the oncolytic adenovirus armed with P55-HTERT-HRE-TRAIL, which exhibited enhanced anti-tumor activity and improved survival, is a promising candidate for virotherapy of TNBC. 相似文献
998.
《Expert opinion on biological therapy》2013,13(11):1519-1524
Introduction: Advanced malignancies that are refractory to standard chemotherapy have few treatment options. Conatumumab is an investigational, fully human monoclonal agonist antibody directed at human death receptor DR5, which is expressed in multiple advanced cancers. Areas covered: The rationale for the use of conatumumab based on in vitro, in vivo, Phase I, and Phase II data will be discussed. Expert opinion: Conatumumab, at a dose of 20 mg/kg every 2 weeks, has demonstrated acceptable safety and tolerability in patients with advanced tumors based on available and published data. Further clinical trials are underway evaluating the use of conatumumab in combination with chemotherapeutic and targeted agents. 相似文献
999.
Sermin Genc Mehtap Yuksel Egrilmez Erdem Yaka Zahide Cavdar Leyla Iyilikci Gorsev Yener Kursad Genc 《Neurological sciences》2009,30(3):263-267
In the present study, we determined the significance of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in
Alzheimer’s disease (AD). We characterized the expression of TRAIL protein in the cerebrospinal fluid (CSF) and serum with
ELISA and TRAIL mRNA in the peripheral blood mononuclear cells (PBMCs) with real-time PCR in 22 patients with AD and 20 control
cases. We could not find TRAIL protein in the CSF samples. The concentration of TRAIL protein in sera from patients with AD
was not different from controls. However, there was an inverse correlation between serum TRAIL levels and Mini-Mental State
Examination scores in AD patients. Also we did not find significant difference in TRAIL mRNA in the PBMCs of patients with
AD when compared with control group. Our data indicate that TRAIL serum level decreases in the late stage of disease. 相似文献
1000.